| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Enliven Therapeutics, Inc. (ELVN) has 10 insiders with recent SEC Form 4 filings, including 0 buys and 19 sells. ELVN is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 890.4K | $40.16M | - | |
| CEO | 875.0K | $39.46M | - | |
| Other | 740.2K | $33.38M | - | |
| 10% | 245.7K | $11.08M | -281,408 | |
| COO | 215.0K | $9.70M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 9, 2024 | Kintz Samuel51 | President And CEO | Sell | 29,977 | $28.07 | $841,334.38 | -0.7% | -15.4% | -24.5% | |
| Oct 9, 2024 | Lyssikatos Joseph P50 | Chief Scientific Officer | Sell | 51,145 | $28.11 | $1,437,585.19 | -1.2% | -15.4% | -24.5% | |
| Oct 8, 2024 | Ballal Rahul D.70 | Director | Sale+OE | 10,420 | $28.17 | $293,557.45 | -31.8% | -14.1% | -27.5% | |
| Oct 7, 2024 | Hohl Benjamin60 | Chief Financial Officer | Sale+OE | 11,488 | $27.51 | $316,014.07 | -100% | -12.3% | -26.7% | |
| Oct 7, 2024 | Lyssikatos Joseph P50 | Chief Scientific Officer | Sell | 10,229 | $27.54 | $281,664.00 | -0.5% | -12.3% | -26.7% | |
| Oct 7, 2024 | Kintz Samuel51 | President And CEO | Sell | 14,936 | $27.51 | $410,866.94 | -0.7% | -12.3% | -26.7% | |
| Oct 4, 2024 | Heyman Richard A.74 | Director | Sell | 2,825 | $27.51 | $77,703.60 | -2.2% | -13.2% | -28.8% | |
| Oct 1, 2024 | Lyssikatos Joseph P50 | Chief Scientific Officer | Sell | 527 | $27.54 | $14,512.10 | - | -13.9% | -23.8% | |
| Oct 1, 2024 | Kintz Samuel51 | President And CEO | Sell | 526 | $27.54 | $14,484.51 | - | -13.9% | -23.8% | |
| Oct 1, 2024 | Hohl Benjamin60 | Chief Financial Officer | Sale+OE | 521 | $27.54 | $14,346.88 | -100% | -13.9% | -23.8% |